This information is general in nature and may not be construed as personal advice.

Gamma Wealth Group is pleased to offer investors to participate in a right issue shortfall for Control Bionics (ASX Code: CBL).

CBL is medical device company assisting patients whose ability to communicate verbally or via text and social media is compromised by illnesses such as Motor Neurone Disease (MND) and Amyotrophic Lateral Sclerosis (ALS).  It uses smart algorithms to detect, synthesise and convert electromyography (EMG) signals into code to control relevant electronic devices.  The company operates in Australia, North America, Singapore and Japan.

Since the company listed on the ASX in late 2020, it has increased its revenue by over 50% but its share price has fallen sharply from 60 cents to 5 cents.  There are several reasons for this sharp selldown that we can personally discuss further.  The company is now completing a rights issue at 4 cents and Gamma Wealth Group has the ability to offer clients the opportunity to participate in this discounted rights issue.  The business requires additional capital from the rights issue to allow it to breakeven in 2024.

Key Highlights:

• Forecasting organic revenue growth in excess of over 30% and $8m in revenue for 2024
   
• Awarded the 4^th most innovative Australian Healthcare company in 2023 by  The Australian Financial Review (AFR)
   
• A new experienced and disciplined CEO who has personally invested in the company
   
• Opportunities to further expand into Japan
   
• Well supported by NDIS in Australia
   
• Recently signed MND Queensland
   
• Opportunity for further growth from DROVE (the world’s first autonomous driving wheelchair without the use of a joystick).  Expected approval from Therapeutic Goods Administration (TGA) by April 2024.
   
• Potential to assist with other illnesses that affect general mobility

The major products for Control Bionics are:

1.       NeuroNode

2.       Eyegaze Duo

3.       Uno Touch

4.       Drove Video

Please see more about the company by clicking below.

https://www.controlbionics.com/

Also, please view their latest AGM Presentation.

https://gammawealthgroup.app.box.com/s/x2ecd3cl03mfpzrjili9e9r513frszo2

CBL is a small, innovative medical device company that is considered highly speculative with potential to grow.  It may be appropriate for those people who understand risk and are willing to withstand volatility.